The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
The challenge of new drug discovery for tuberculosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationAn interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Tuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932
Cited by
The antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
“Therefore, in the pre-NP era, three methods used to overcome antibiotic resistance were the development of new drugs, high-dose administration of an antibiotic,(6) and the combination of multiple antibiotics.(30,31) However, the production of novel antibiotics could not keep up with the mutation of bacteria, and intol…”
MethodAdvances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Mycobacterium tuberculosis: success through dormancy
Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 696
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Duncton, M. A. J. (2011) · MedChemComm · doi:10.1039/c1md00134e · Cited by 607
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.69 · Cited by 484
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303575 · Cited by 380
Self-citationAlvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
Harbut, M. B., Vilchèze, C., Luo, X., Hensler, M. E., Guo, H., Yang, B., Chatterjee, A. K., Nizet, V., Jacobs, W. R., Schultz, P. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504022112 · Cited by 330
Fueling Open‐Source Drug Discovery: 177 Small‐Molecule Leads against Tuberculosis
Ballell, L., Bates, R. H., Young, R. J., Alvarez‐Gomez, D., Alvarez‐Ruiz, E., Barroso, V., Blanco, D., Crespo, B., Escribano, J., González, R., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201200428 · Cited by 308
Metabolic regulation of antibiotic resistance
Martínez, J. L., & Rojo, F. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00282.x · Cited by 304
Preiss, L., Langer, J. D., Yildiz, Ö., Eckhardt-Strelau, L., Guillemont, J. E. G., Koul, A., & Meier, T. (2015) · Science Advances · doi:10.1126/sciadv.1500106 · Cited by 293
Self-citationKoul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J.-M., Schulz, M., Lu, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 293
Self-citationAntibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Graphitic carbon nitride-based materials for photocatalytic antibacterial application
Kong, X., Liu, X., Zheng, Y., Chu, P. K., Zhang, Y., & Wu, S. (2021) · Materials Science and Engineering: R: Reports · doi:10.1016/j.mser.2021.100610 · Cited by 259
Phenotypic Resistance to Antibiotics
Corona, F., & Martinez, J. (2013) · Antibiotics · doi:10.3390/antibiotics2020237 · Cited by 205
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen
Ramón-García, S., Ng, C., Anderson, H., Chao, J. D., Zheng, X., Pfeifer, T., Av-Gay, Y., Roberge, M., & Thompson, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-11 · Cited by 185
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
“era where TB is untreatable, the discovery of unique drug targets and novel inhibitory compounds can be considered invaluable in terms of meeting the current and future therapeutic needs to relieve the burden of TB cases worldwide [4].”
BackgroundO'Neill, T. E., Li, H., Colquhoun, C. D., Johnson, J. A., Webster, D., & Gray, C. A. (2014) · Phytochemical Analysis · doi:10.1002/pca.2516 · Cited by 31
Limenih, Y. A., & Workie, D. L. (2019) · BMC Public Health · doi:10.1186/s12889-019-6500-3 · Cited by 27
Metadata
- Authors
- Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K.
- Venue
- Nature
- Published
- 2011-01
- Volume
- 469
- Issue
- 7331
- Pages
- 483-490
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1986106712
- Cited by
- 1,042
- References
- 59
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.